Patent ID: 8563003

Claim:
A method of treating a human patient having a cancer consisting of administering active agents for the treatment of cancer to a human patient in need thereof, wherein the active agents consist of (i) a vaccine and (ii) an immune modulator agent; wherein the vaccine consists essentially of a self antigen associated with said cancer and an adjuvant, wherein said self antigen is epidermal growth factor, wherein said epidermal growth factor is coupled to a carrier protein; wherein the immune modulator agent is one or several chemotherapeutic agent(s); and further wherein the administration comprises the steps: (a) immunizing the human patient with 2-5 doses of the vaccine to raise the titers of measurable serum antibodies in the human patient to at least double the initial titer measured before beginning immunizations; (b) treating the human patient with 2-6 doses of the immune modulator agent to induce a transient depletion of peripheral T cells; and (c) immunizing the human patient again with monthly doses of the vaccine of step (a), wherein a first dose is administered when regeneration of the peripheral T cells begins, wherein the human patient having the cancer is treated.